Antibodies 2013, 2(3), 517-534; doi:10.3390/antib2030517
Review

T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications

Received: 15 August 2013; in revised form: 22 August 2013 / Accepted: 22 August 2013 / Published: 17 September 2013
(This article belongs to the Special Issue Recombinant Immunotoxins)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Major histocompatibility complex (MHC) class I molecules are key in the immune response against malignant cells by shaping the T-cell repertoire and presenting peptides from endogenous antigens to CD8+ cytotoxic T cells. Because of their unique specificity, MHC-peptide complexes are a desirable target for novel immunotherapeutic approaches. These complexes can be targeted by recombinant T-cell receptors (TCRs). However, most TCRs produced thus far have affinities which are too low for target detection under normal assay conditions, and limited stability (due to their generation in a single-chain version). Developing high-affinity soluble antibody molecules endowed with a TCR-like specificity toward tumor epitopes, termed TCR-like antibodies, addresses the low affinity of TCRs. These TCR-like antibodies are being developed as a new immunotherapeutic class for targeting tumor cells and mediating their specific killing. In addition, these antibodies are valuable research reagents enabling the study of human class I peptide-MHC ligand-presentation and TCR–peptide–MHC interactions.
Keywords: antibodies; antibody engineering; immunotoxins; MHC-peptide complex; phage display; recombinant antibodies; T-cell receptor; cancer immunotherapy
PDF Full-text Download PDF Full-Text [215 KB, uploaded 17 September 2013 17:25 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Cohen, M.; Reiter, Y. T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications. Antibodies 2013, 2, 517-534.

AMA Style

Cohen M, Reiter Y. T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications. Antibodies. 2013; 2(3):517-534.

Chicago/Turabian Style

Cohen, Maya; Reiter, Yoram. 2013. "T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications." Antibodies 2, no. 3: 517-534.

Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert